Vimarsana
Biggest News Aggregation in the World

Front Med News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Front Med. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Front Med Today - Breaking & Trending Today

Colds and Flu in the age of Covid-19 - Vimarsana News

Colds and Flu in the age of Covid-19

Embrace the Winter Warrior within with the Adcock Ingram Range, featuring Panado®, Cepacol®, Compral®, and ViralGuard™.

Study: Anxiety May Increase Acute Exacerbation Risk for Older Patients With COPD - Vimarsana News

Study: Anxiety May Increase Acute Exacerbation Risk for Older Patients With COPD

Older patients with chronic obstructive pulmonary disease (COPD) and anxiety exhibited exacerbated symptoms, increased comorbidities, and frequent acute exacerbations of COPD (AECOPD), emphasizing the need for routine psychiatric screening in COPD management.

Source: ajmc.com
Vitamin D Supplementation Linked to Reduced In-Hospital, ICU Mortality in Patients With COPD - Vimarsana News

Vitamin D Supplementation Linked to Reduced In-Hospital, ICU Mortality in Patients With COPD

Vitamin D supplementation may decrease in-hospital and intensive care unit (ICU) mortality in patients with chronic obstructive pulmonary disease (COPD), a study found.

Source: ajmc.com
Intravenous Iron Boosts Hemoglobin Levels in Children with Anemia, IBD - Vimarsana News

Intravenous Iron Boosts Hemoglobin Levels in Children with Anemia, IBD

Treatment with intravenous iron therapy proves more efficacious than oral or no iron therapy in improving hemoglobin in pediatric patients admitted with IBD and IDA.

ODESSA-UC Study Compares Dose Escalation in Vedolizumab, AntiTNF-α for Ulcerative Colitis - Vimarsana News

ODESSA-UC Study Compares Dose Escalation in Vedolizumab, AntiTNF-α for Ulcerative Colitis

Results showed patients treated with vedolizumab experienced less dose escalation and were at a decreased risk of requiring dose escalation compared to patients treated with adalimumab and infliximab.